The Justice Department has announced an $8.33 million settlement with Modern Nuclear to resolve allegations that the company paid unlawful kickbacks to medical practices tied to its mobile PET scan services, leading to claims reimbursed by federal healthcare programs. While the matter was resolved without a determination of liability, the settlement is a notable reminder that the government continues to treat kickback-driven referral arrangements as a core healthcare-fraud enforcement priority.

According to the government’s allegations, the company’s financial arrangements with physician practices crossed the line from legitimate business relationships into conduct that potentially violated the Anti-Kickback Statute. That matters because claims submitted to federal programs that are allegedly tainted by kickbacks can also trigger liability under the False Claims Act, dramatically increasing exposure through treble damages and per-claim penalties.

For legal and compliance professionals, the case underscores a recurring enforcement theory: even when the underlying services are medically appropriate, the manner in which referrals are obtained can create FCA risk. In sectors like mobile imaging, diagnostics, and outsourced service lines—where providers often partner closely with physician groups—the structure of compensation, service agreements, and marketing support can become central issues in a government investigation.

The settlement also highlights why these cases remain attractive to federal enforcers and whistleblowers alike. Anti-kickback allegations can be fact-intensive, but they often turn on familiar categories of evidence: payment formulas, lease or staffing arrangements, free or below-market benefits, internal communications about referrals, and whether compensation was tied—directly or indirectly—to federal program business. For defendants, that means exposure can arise not only from formal contracts, but from operational practices that diverge from documented compliance policies.

For litigators, this is another data point showing DOJ’s continued willingness to use the False Claims Act as a vehicle for policing provider relationships. For in-house counsel and compliance teams, it is a practical warning to revisit fair-market-value analyses, referral-source contracting, and audits of arrangements involving high-volume physician practices. Mobile and outpatient service models can present heightened risk because they sit at the intersection of convenience, referral economics, and federal reimbursement.

The broader takeaway is straightforward: in the healthcare space, commercial strategy and fraud-and-abuse law remain tightly linked. Companies that rely on physician-facing growth models should expect sustained scrutiny where federal healthcare dollars are in the payment chain, and should document—with precision—why each financial relationship is compliant before regulators ask the question for them.